Meeting
2022 ASCO Annual Meeting
Better (a little) late than never: The impact of steroidal treatment initiation timing on the outcome of patients with melanoma treated with immunotherapy.
Authors
Nethanel Asher
The Ella Lemelbaum Institute for Immuno-Oncology at Sheba Medical Center, Ramat Gan, Israel
Nethanel Asher , Neta Bar-Hai , Guy Ben-betzalel , Ronen Stoff , Shirly Grynberg , Jacob Schachter , Ronnie Shapira-Frommer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9544)
DOI
10.1200/JCO.2022.40.16_suppl.9544
Abstract #
9544
Poster Bd #
137
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors (ICIs) for in-transit melanoma.
First Author: Emilia Nan Tie
Poster
2018 ASCO Annual Meeting
Hyperacute toxicity with combination ipilimumab (ipi) and anti-PD1 immunotherapy.
First Author: Helen Clare Dearden
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy of immune checkpoint inhibitors in patients with brain metastasis from NSCLC, RCC, and melanoma.
First Author: Adam Lauko
Poster
2024 ASCO Annual Meeting
ADU-1604, a novel CTLA-4 blocking antibody, to modulate pharmacodynamic markers in patients with PD1 relapse/refractory melanoma.
First Author: Guillermo De Velasco